{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:41:03Z","timestamp":1792276863700,"version":"4.4.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the University Basic Scientific Research Project of the Department of Education of Liaoning Province","award":["LJ112610159019"],"award-info":[{"award-number":["LJ112610159019"]}]},{"name":"345 talent project plan\u201d of Shengjing Hospital of China Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02408-9","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:17:01Z","timestamp":1792275421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6178-8220","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8787-0845","authenticated-orcid":false,"given":"Xiaodan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8689-4305","authenticated-orcid":false,"given":"Sha","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-8317","authenticated-orcid":false,"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"2408_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2021","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"2408_CR2","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334. https:\/\/doi.org\/10.1016\/s0140-6736(23)01301-6.","DOI":"10.1016\/s0140-6736(23)01301-6"},{"issue":"4","key":"2408_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4235\/agmr.19.0038","volume":"23","author":"HC Jang","year":"2019","unstructured":"Jang HC. Diabetes and muscle dysfunction in older adults. Ann Geriatr Med Res. 2019;23(4):160\u20134. https:\/\/doi.org\/10.4235\/agmr.19.0038.","journal-title":"Ann Geriatr Med Res"},{"issue":"1","key":"2408_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-024-04668-0","volume":"24","author":"LB Freire","year":"2024","unstructured":"Freire LB, Brasil-Neto JP, da Silva ML, Miranda MGC, de Mattos Cruz L, Martins WR, et al. Risk factors for falls in older adults with diabetes mellitus: systematic review and meta-analysis. BMC Geriatr. 2024;24(1):201. https:\/\/doi.org\/10.1186\/s12877-024-04668-0.","journal-title":"BMC Geriatr"},{"issue":"9","key":"2408_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102835","volume":"17","author":"A Marcotte-Ch\u00e9nard","year":"2023","unstructured":"Marcotte-Ch\u00e9nard A, Oliveira B, Little JP, Candow DG. Sarcopenia and type 2 diabetes: pathophysiology and potential therapeutic lifestyle interventions. Diabetes Metab Syndr. 2023;17(9):102835. https:\/\/doi.org\/10.1016\/j.dsx.2023.102835.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"2408_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01998-w","volume":"17","author":"H Bai","year":"2025","unstructured":"Bai H, Liu Y, Zhang L, Song L, Pan Y, Long Z, et al. Sarcopenia as a predictor of negative health outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17(1):416. https:\/\/doi.org\/10.1186\/s13098-025-01998-w.","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"2408_CR7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","journal-title":"Diabetologia"},{"issue":"12","key":"2408_CR8","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390. https:\/\/doi.org\/10.2337\/dci22-0027.","journal-title":"Diabetes Care"},{"issue":"8","key":"2408_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081958","volume":"10","author":"E Massimino","year":"2021","unstructured":"Massimino E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells. 2021;10(8):1958. https:\/\/doi.org\/10.3390\/cells10081958.","journal-title":"Cells"},{"issue":"8","key":"2408_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61081399","volume":"61","author":"I Bujdei-Tebeic\u0103","year":"2025","unstructured":"Bujdei-Tebeic\u0103 I, Mihai DA, Pantea-Stoian AM, \u0218tefan SD, Stoicescu C, Serafinceanu C. Effects of blood-glucose lowering therapies on body composition and muscle outcomes in type 2 diabetes: a narrative review. Medicina (Kaunas). 2025;61(8):1399. https:\/\/doi.org\/10.3390\/medicina61081399.","journal-title":"Medicina (Kaunas)"},{"key":"2408_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155585","volume":"144","author":"Y Hashimoto","year":"2023","unstructured":"Hashimoto Y, Takahashi F, Okamura T, Hamaguchi M, Fukui M. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes. Metabolism. 2023;144:155585. https:\/\/doi.org\/10.1016\/j.metabol.2023.155585.","journal-title":"Metabolism"},{"key":"2408_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1203666","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Qi Z, Wang Y, Song D, Zhu D. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1203666. https:\/\/doi.org\/10.3389\/fendo.2023.1203666.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2408_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","volume":"14","author":"Z Memel","year":"2025","unstructured":"Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14(1):63. https:\/\/doi.org\/10.1007\/s13668-025-00649-w.","journal-title":"Curr Nutr Rep."},{"issue":"12","key":"2408_CR14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s13300-023-01481-7","volume":"14","author":"S Jahangiri","year":"2023","unstructured":"Jahangiri S, Malek M, Kalra S, Khamseh ME. The effects of sodium-glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review. Diabetes Ther. 2023;14(12):2015\u201330. https:\/\/doi.org\/10.1007\/s13300-023-01481-7.","journal-title":"Diabetes Ther"},{"issue":"5","key":"2408_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70194","volume":"42","author":"R Jobanputra","year":"2026","unstructured":"Jobanputra R, Sargeant JA, Plekhanova T, James E, Almaqhawi A, Webb DR, et al. The effects of glucagon-like peptide-1 receptor agonists and sodium-glucose o-Ttransporter-2 inhibitors on lean body mass in humans: a systematic review and meta-analysis of randomised controlled trials. Diabetes Metab Res Rev. 2026;42(5):e70194. https:\/\/doi.org\/10.1002\/dmrr.70194.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2408_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jocd.2015.05.063","volume":"18","author":"PM Cawthon","year":"2015","unstructured":"Cawthon PM. Assessment of lean mass and physical performance in Ssrcopenia. J Clin Densitom. 2015;18(4):467\u201371. https:\/\/doi.org\/10.1016\/j.jocd.2015.05.063.","journal-title":"J Clin Densitom"},{"issue":"2","key":"2408_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41430-018-0335-3","volume":"73","author":"LC Ward","year":"2019","unstructured":"Ward LC. Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation. Eur J Clin Nutr. 2019;73(2):194\u20139. https:\/\/doi.org\/10.1038\/s41430-018-0335-3.","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"2408_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s41999-022-00706-5","volume":"13","author":"PM Cawthon","year":"2022","unstructured":"Cawthon PM, Visser M, Arai H, \u00c1vila-Funes JA, Barazzoni R, Bhasin S, et al. Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee. Eur Geriatr Med. 2022;13(6):1239\u201344. https:\/\/doi.org\/10.1007\/s41999-022-00706-5.","journal-title":"Eur Geriatr Med"},{"issue":"1","key":"2408_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing"},{"issue":"11","key":"2408_CR20","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1038\/s43587-025-01004-y","volume":"5","author":"LK Chen","year":"2025","unstructured":"Chen LK, Hsiao FY, Akishita M, Assantachai P, Lee WJ, Lim WS, et al. A focus shift from sarcopenia to muscle health in the Asian Working Group for Sarcopenia 2025 Consensus Update. Nat Aging. 2025;5(11):2164\u201375. https:\/\/doi.org\/10.1038\/s43587-025-01004-y.","journal-title":"Nat Aging"},{"issue":"4","key":"2408_CR21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11154-023-09871-9","volume":"25","author":"RD de Luis","year":"2024","unstructured":"de Luis RD, G\u00f3mez JC, Garc\u00eda-Almeida JM, Vallo FG, Rolo GG, G\u00f3mez JJL, et al. Diabetic sarcopenia: a proposed muscle screening protocol in people with diabetes. Expert document Rev Endocr Metab Disord. 2024;25(4):651\u201361. https:\/\/doi.org\/10.1007\/s11154-023-09871-9.","journal-title":"Expert document. Rev Endocr Metab Disord."},{"issue":"8","key":"2408_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jamda.2013.05.018","volume":"14","author":"TK Malmstrom","year":"2013","unstructured":"Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531\u20132. https:\/\/doi.org\/10.1016\/j.jamda.2013.05.018.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"2408_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022;15(3):321\u201335. https:\/\/doi.org\/10.1159\/000521241.","journal-title":"Obes Facts"},{"issue":"6","key":"2408_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/jdi.13070","volume":"10","author":"K Sugimoto","year":"2019","unstructured":"Sugimoto K, Tabara Y, Ikegami H, Takata Y, Kamide K, Ikezoe T, et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus. J Diabetes Investig. 2019;10(6):1471\u20139. https:\/\/doi.org\/10.1111\/jdi.13070.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2408_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13098-021-00707-7","volume":"13","author":"Y Ai","year":"2021","unstructured":"Ai Y, Xu R, Liu L. The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):93. https:\/\/doi.org\/10.1186\/s13098-021-00707-7.","journal-title":"Diabetol Metab Syndr"},{"key":"2408_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clnu.2025.10.007","volume":"55","author":"R Barazzoni","year":"2025","unstructured":"Barazzoni R, Sievenpiper JL, Genton L, Kendall CW, Ballesteros-Pomar MD, Giosu\u00e8 A, et al. Sarcopenic diabetes is an under-recognized and unmet clinical priority: a call for action from the European Society for Clinical Nutrition and Metabolism and the Diabetes Nutrition Study Group. Clin Nutr. 2025;55:208\u201318. https:\/\/doi.org\/10.1016\/j.clnu.2025.10.007.","journal-title":"Clin Nutr"},{"issue":"Suppl. 2","key":"2408_CR27","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.2337\/dc09-S302","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl. 2):S157\u201363. https:\/\/doi.org\/10.2337\/dc09-S302.","journal-title":"Diabetes Care"},{"key":"2408_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.782391","volume":"12","author":"YS Qiao","year":"2021","unstructured":"Qiao YS, Chai YH, Gong HJ, Zhuldyz Z, Stehouwer CDA, Zhou JB, et al. The association between diabetes mellitus and risk of sarcopenia: accumulated evidences from observational studies. Front Endocrinol (Lausanne). 2021;12:782391. https:\/\/doi.org\/10.3389\/fendo.2021.782391.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2408_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep38937","volume":"6","author":"T Wang","year":"2016","unstructured":"Wang T, Feng X, Zhou J, Gong H, Xia S, Wei Q, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep. 2016;6:38937. https:\/\/doi.org\/10.1038\/srep38937.","journal-title":"Sci Rep"},{"issue":"14","key":"2408_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/nu15143167","volume":"15","author":"B Alabadi","year":"2023","unstructured":"Alabadi B, Civera M, De la Rosa A, Martinez-Hervas S, Gomez-Cabrera MC, Real JT. Low muscle mass is associated with poorer glycemic control and higher oxidative stress in older patients with type 2 diabetes. Nutrients. 2023;15(14):3167. https:\/\/doi.org\/10.3390\/nu15143167.","journal-title":"Nutrients"},{"key":"2408_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.913207","volume":"13","author":"X Shi","year":"2022","unstructured":"Shi X, Liu W, Zhang L, Xiao F, Huang P, Yan B, et al. Sex-specific associations between low muscle mass and glucose fluctuations in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:913207. https:\/\/doi.org\/10.3389\/fendo.2022.913207.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2408_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.783363","volume":"12","author":"F Takahashi","year":"2021","unstructured":"Takahashi F, Hashimoto Y, Kaji A, Sakai R, Okamura T, Kitagawa N, et al. Sarcopenia is associated with a risk of mortality in people with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:783363. https:\/\/doi.org\/10.3389\/fendo.2021.783363.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"16","key":"2408_CR33","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/nu17162622","volume":"17","author":"S Yamamoto","year":"2025","unstructured":"Yamamoto S, Hashimoto Y, Takahashi F, Sakai R, Saijo Y, Munekawa C, et al. Mortality risk of sarcopenia and malnutrition in older patients with type 2 diabetes mellitus. Nutrients. 2025;17(16):2622. https:\/\/doi.org\/10.3390\/nu17162622.","journal-title":"Nutrients"},{"key":"2408_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.111063","volume":"207","author":"MV Beretta","year":"2024","unstructured":"Beretta MV, de Paula TP, da Costa Rodrigues T, Steemburgo T. Prolonged hospitalization and 1-year mortality are associated with sarcopenia and malnutrition in older patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2024;207:111063. https:\/\/doi.org\/10.1016\/j.diabres.2023.111063.","journal-title":"Diabetes Res Clin Pract"},{"key":"2408_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/dmso.S186600","volume":"12","author":"J Mesinovic","year":"2019","unstructured":"Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057\u201372. https:\/\/doi.org\/10.2147\/dmso.S186600.","journal-title":"Diabetes Metab Syndr Obes."},{"key":"2408_CR36","doi-asserted-by":"publisher","unstructured":"13. Older adults: standards of care in diabetes: 2025. Diabetes Care. 2025;48(1 Suppl. 1):S266\u201382. https:\/\/doi.org\/10.2337\/dc25-S013.","DOI":"10.2337\/dc25-S013"},{"issue":"8","key":"2408_CR37","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc11-2202","volume":"35","author":"S Volpato","year":"2012","unstructured":"Volpato S, Bianchi L, Lauretani F, Lauretani F, Bandinelli S, Guralnik JM, et al. Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care. 2012;35(8):1672\u20139. https:\/\/doi.org\/10.2337\/dc11-2202.","journal-title":"Diabetes Care"},{"issue":"5","key":"2408_CR38","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","volume":"148","author":"VT Samuel","year":"2012","unstructured":"Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852\u201371. https:\/\/doi.org\/10.1016\/j.cell.2012.02.017.","journal-title":"Cell"},{"issue":"23","key":"2408_CR39","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMc1412427","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(23):2237\u20138. https:\/\/doi.org\/10.1056\/NEJMc1412427.","journal-title":"N Engl J Med"},{"issue":"9","key":"2408_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/obr.12862","volume":"20","author":"RCR Meex","year":"2019","unstructured":"Meex RCR, Blaak EE, van Loon LJC. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev. 2019;20(9):1205\u201317. https:\/\/doi.org\/10.1111\/obr.12862.","journal-title":"Obes Rev"},{"issue":"3","key":"2408_CR41","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1096\/fj.04-2640fje","volume":"19","author":"D Cuthbertson","year":"2005","unstructured":"Cuthbertson D, Smith K, Babraj J, Leese G, Waddell T, Atherton P, et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005;19(3):422\u20134. https:\/\/doi.org\/10.1096\/fj.04-2640fje.","journal-title":"FASEB J"},{"issue":"6","key":"2408_CR42","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1096\/fj.05-4607fje","volume":"20","author":"BB Rasmussen","year":"2006","unstructured":"Rasmussen BB, Fujita S, Wolfe RR, Mittendorfer B, Roy M, Rowe VL, et al. Insulin resistance of muscle protein metabolism in aging. FASEB J. 2006;20(6):768\u20139. https:\/\/doi.org\/10.1096\/fj.05-4607fje.","journal-title":"FASEB J"},{"issue":"2","key":"2408_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jdiacomp.2007.06.008","volume":"22","author":"J Ib\u00e1\u00f1ez","year":"2008","unstructured":"Ib\u00e1\u00f1ez J, Gorostiaga EM, Alonso AM, Forga L, Arg\u00fcelles I, Larri\u00f3n JL, et al. Lower muscle strength gains in older men with type 2 diabetes after resistance training. J Diabet Complicat. 2008;22(2):112\u20138. https:\/\/doi.org\/10.1016\/j.jdiacomp.2007.06.008.","journal-title":"J Diabet Complicat"},{"issue":"5","key":"2408_CR44","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11154-025-09947-8","volume":"26","author":"AA Al-Awadi","year":"2025","unstructured":"Al-Awadi AA, Gray SR, Al-Ozairi E. Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes? Rev Endocr Metab Disord. 2025;26(5):857\u201370. https:\/\/doi.org\/10.1007\/s11154-025-09947-8.","journal-title":"Rev Endocr Metab Disord"},{"key":"2408_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.01045","volume":"8","author":"S Dalle","year":"2025","unstructured":"Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol. 2025;8:1045. https:\/\/doi.org\/10.3389\/fphys.2017.01045.","journal-title":"Front Physiol"},{"issue":"6","key":"2408_CR46","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/0148607108324585","volume":"32","author":"GL Jensen","year":"2008","unstructured":"Jensen GL. Inflammation: roles in aging and sarcopenia. JPEN J Parenter Enteral Nutr. 2008;32(6):656\u20139. https:\/\/doi.org\/10.1177\/0148607108324585.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"7086","key":"2408_CR47","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nature04634","volume":"440","author":"N Houstis","year":"2006","unstructured":"Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944\u20138. https:\/\/doi.org\/10.1038\/nature04634.","journal-title":"Nature"},{"issue":"3","key":"2408_CR48","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1172\/jci37048","volume":"119","author":"EJ Anderson","year":"2009","unstructured":"Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, et al. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009;119(3):573\u201381. https:\/\/doi.org\/10.1172\/jci37048.","journal-title":"J Clin Invest"},{"issue":"1","key":"2408_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1242\/dmm.010389","volume":"6","author":"P Bonaldo","year":"2013","unstructured":"Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 2013;6(1):25\u201339. https:\/\/doi.org\/10.1242\/dmm.010389.","journal-title":"Dis Model Mech"},{"issue":"6","key":"2408_CR50","doi-asserted-by":"publisher","first-page":"C1291","DOI":"10.1152\/ajpcell.00531.2009","volume":"298","author":"M Sandri","year":"2010","unstructured":"Sandri M. Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. Am J Physiol Cell Physiol. 2010;298(6):C1291\u20137. https:\/\/doi.org\/10.1152\/ajpcell.00531.2009.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2408_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285\u201398. https:\/\/doi.org\/10.1016\/j.cell.2004.09.027.","journal-title":"Cell"},{"issue":"3","key":"2408_CR52","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1096\/fj.04-2364com","volume":"19","author":"YP Li","year":"2005","unstructured":"Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle. FASEB J. 2005;19(3):362\u201370. https:\/\/doi.org\/10.1096\/fj.04-2364com.","journal-title":"FASEB J"},{"issue":"6","key":"2408_CR53","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.cmet.2024.02.014","volume":"36","author":"E Espino-Gonzalez","year":"2024","unstructured":"Espino-Gonzalez E, Dalbram E, Mounier R, Gondin J, Farup J, Jessen N, et al. Impaired skeletal muscle regeneration in diabetes: from cellular and molecular mechanisms to novel treatments. Cell Metab. 2024;36(6):1204\u201336. https:\/\/doi.org\/10.1016\/j.cmet.2024.02.014.","journal-title":"Cell Metab"},{"key":"2408_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1375610","volume":"15","author":"Z Liu","year":"2024","unstructured":"Liu Z, Guo Y, Zheng C. Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy. Front Endocrinol (Lausanne). 2024;15:1375610. https:\/\/doi.org\/10.3389\/fendo.2024.1375610.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2408_CR55","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1152\/japplphysiol.00670.2007","volume":"103","author":"JM Haus","year":"2007","unstructured":"Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol (1985). 2007;103(6):2068\u201376. https:\/\/doi.org\/10.1152\/japplphysiol.00670.2007.","journal-title":"J Appl Physiol (1985)"},{"issue":"11","key":"2408_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering8110168","volume":"8","author":"LC Olson","year":"2021","unstructured":"Olson LC, Redden JT, Schwartz Z, Cohen DJ, McClure MJ. Advanced glycation end-products in skeletal muscle aging. Bioengineering (Basel). 2021;8(11):168. https:\/\/doi.org\/10.3390\/bioengineering8110168.","journal-title":"Bioengineering (Basel)"},{"issue":"3","key":"2408_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1302\/2046-3758.143.Bjr-2024-0252.R1","volume":"14","author":"Z Guo","year":"2025","unstructured":"Guo Z, Li H, Jiang S, Rahmati M, Su J, Yang S, et al. The role of AGEs in muscle ageing and sarcopenia. Bone Joint Res. 2025;14(3):185\u201398. https:\/\/doi.org\/10.1302\/2046-3758.143.Bjr-2024-0252.R1.","journal-title":"Bone Joint Res"},{"key":"2408_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2022.111744","volume":"209","author":"A Granic","year":"2023","unstructured":"Granic A, Hurst C, Dismore L, Dodds RM, Witham MD, Robinson SM, et al. Advanced glycation end products in skeletal muscle health and sarcopenia: a systematic review of observational studies. Mech Ageing Dev. 2023;209:111744. https:\/\/doi.org\/10.1016\/j.mad.2022.111744.","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"2408_CR59","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1210\/clinem\/dgab632","volume":"107","author":"K Waqas","year":"2022","unstructured":"Waqas K, Chen J, Trajanoska K, Ikram MA, Uitterlinden AG, Rivadeneira F, et al. Skin autofluorescence, a noninvasive biomarker for advanced glycation end-products, is associated with sarcopenia. J Clin Endocrinol Metab. 2022;107(2):e793-803. https:\/\/doi.org\/10.1210\/clinem\/dgab632.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2408_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00421-009-1192-5","volume":"108","author":"RD Semba","year":"2010","unstructured":"Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol. 2010;108(1):191\u20135. https:\/\/doi.org\/10.1007\/s00421-009-1192-5.","journal-title":"Eur J Appl Physiol"},{"key":"2408_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/586385","author":"K Sun","year":"2012","unstructured":"Sun K, Semba RD, Fried LP, Schaumberg DA, Ferrucci L, Varadhan R. Elevated serum carboxymethyl-lysine, an advanced glycation end product, predicts severe walking disability in older women: the Women\u2019s Health and Aging Study I. J Aging Res. 2012. https:\/\/doi.org\/10.1155\/2012\/586385.","journal-title":"J Aging Res"},{"issue":"3","key":"2408_CR62","doi-asserted-by":"publisher","first-page":"e1105","DOI":"10.1210\/clinem\/dgad640","volume":"109","author":"X Zhang","year":"2024","unstructured":"Zhang X, Chen X, Li S, Gao M, Han P, Cao L, et al. Association between advanced glycation end products and sarcopenia: the mediating role of Ooteoporosis. J Clin Endocrinol Metab. 2024;109(3):e1105\u201316. https:\/\/doi.org\/10.1210\/clinem\/dgad640.","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2408_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186948","volume":"21","author":"AJ Genders","year":"2020","unstructured":"Genders AJ, Holloway GP, Bishop DJ. Are alterations in skeletal muscle mitochondria a cause or consequence of insulin resistance? Int J Mol Sci. 2020;21(18):6948. https:\/\/doi.org\/10.3390\/ijms21186948.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2408_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251355996","volume":"53","author":"Z Xie","year":"2025","unstructured":"Xie Z, Li Y, Li X, Zhang J. A review of mitochondrial dysfunction in diabetic sarcopenia: mechanisms, diagnosis, and treatment approaches. J Int Med Res. 2025;53(7):3000605251355996. https:\/\/doi.org\/10.1177\/03000605251355996.","journal-title":"J Int Med Res"},{"issue":"10","key":"2408_CR65","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.2337\/diabetes.51.10.2944","volume":"51","author":"DE Kelley","year":"2002","unstructured":"Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51(10):2944\u201350. https:\/\/doi.org\/10.2337\/diabetes.51.10.2944.","journal-title":"Diabetes"},{"issue":"12","key":"2408_CR66","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1172\/jci25151","volume":"115","author":"K Morino","year":"2005","unstructured":"Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest. 2005;115(12):3587\u201393. https:\/\/doi.org\/10.1172\/jci25151.","journal-title":"J Clin Invest"},{"issue":"2","key":"2408_CR67","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1152\/ajpendo.00426.2017","volume":"315","author":"EM Ripley","year":"2018","unstructured":"Ripley EM, Clarke GD, Hamidi V, Martinez RA, Settles FD, Solis C, et al. Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy study. Am J Physiol Endocrinol Metab. 2018;315(2):E229\u201339. https:\/\/doi.org\/10.1152\/ajpendo.00426.2017.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2408_CR68","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jvs.2012.10.011","volume":"57","author":"F Tecilazich","year":"2013","unstructured":"Tecilazich F, Dinh T, Lyons TE, Guest J, Villafuerte RA, Sampanis C, et al. Postexercise phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in diabetic patients with lower extremity complications. J Vasc Surg. 2013;57(4):997\u20131005. https:\/\/doi.org\/10.1016\/j.jvs.2012.10.011.","journal-title":"J Vasc Surg"},{"issue":"10","key":"2408_CR69","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2337\/dc18-0296","volume":"41","author":"NA Stephens","year":"2018","unstructured":"Stephens NA, Brouwers B, Eroshkin AM, Yi F, Cornnell HH, Meyer C, et al. Exercise response variations in skeletal muscle PCr recovery rate and insulin sensitivity relate to muscle epigenomic profiles in individuals with type 2 diabetes. Diabetes Care. 2018;41(10):2245\u201354. https:\/\/doi.org\/10.2337\/dc18-0296.","journal-title":"Diabetes Care"},{"issue":"2","key":"2408_CR70","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00125-020-05335-w","volume":"64","author":"A Houzelle","year":"2021","unstructured":"Houzelle A, J\u00f6rgensen JA, Schaart G, Daemen S, van Polanen N, Fealy CE, et al. Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity. Diabetologia. 2021;64(2):424\u201336. https:\/\/doi.org\/10.1007\/s00125-020-05335-w.","journal-title":"Diabetologia"},{"issue":"768","key":"2408_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado3022","volume":"16","author":"D Rizo-Roca","year":"2024","unstructured":"Rizo-Roca D, Guimar\u00e3es D, Pendergrast LA, Di Leo N, Chibalin AV, Maqdasy S, et al. Decreased mitochondrial creatine kinase 2 impairs skeletal muscle mitochondrial function independently of insulin in type 2 diabetes. Sci Transl Med. 2024;16(768):eado3022. https:\/\/doi.org\/10.1126\/scitranslmed.ado3022.","journal-title":"Sci Transl Med"},{"issue":"7","key":"2408_CR72","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2337\/db23-0827","volume":"73","author":"SV Ramos","year":"2024","unstructured":"Ramos SV, Distefano G, Lui LY, Cawthon PM, Kramer P, Sipula IJ, et al. Role of cardiorespiratory fitness and mitochondrial oxidative capacity in reduced walk speed of older adults with diabetes. Diabetes. 2024;73(7):1048\u201357. https:\/\/doi.org\/10.2337\/db23-0827.","journal-title":"Diabetes"},{"issue":"3","key":"2408_CR73","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2020.01.015","volume":"31","author":"A Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez A, Hall MN, Lin SC, Hardie DG. AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31(3):472\u201392. https:\/\/doi.org\/10.1016\/j.cmet.2020.01.015.","journal-title":"Cell Metab"},{"issue":"4","key":"2408_CR74","first-page":"186","volume":"9","author":"ML Maltais","year":"2009","unstructured":"Maltais ML, Desroches J, Dionne IJ. Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact. 2009;9(4):186\u201397.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2408_CR75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2019.03.033","volume":"123","author":"BC Collins","year":"2019","unstructured":"Collins BC, Laakkonen EK, Lowe DA. Aging of the musculoskeletal system: how the loss of estrogen impacts muscle strength. Bone. 2019;123:137\u201344. https:\/\/doi.org\/10.1016\/j.bone.2019.03.033.","journal-title":"Bone"},{"issue":"7","key":"2408_CR76","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1506119.","journal-title":"N Engl J Med"},{"issue":"6","key":"2408_CR77","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1210\/jc.2008-2338","volume":"94","author":"FR Sattler","year":"2009","unstructured":"Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab. 2009;94(6):1991\u20132001. https:\/\/doi.org\/10.1210\/jc.2008-2338.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2408_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2215025.","journal-title":"N Engl J Med"},{"issue":"1","key":"2408_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2522\/ptj.20160124","volume":"97","author":"PM Kluding","year":"2017","unstructured":"Kluding PM, Bareiss SK, Hastings M, Marcus RL, Sinacore DR, Mueller MJ. Physical training and activity in people with diabetic peripheral neuropathy: paradigm shift. Phys Ther. 2017;97(1):31\u201343. https:\/\/doi.org\/10.2522\/ptj.20160124.","journal-title":"Phys Ther"},{"issue":"5","key":"2408_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57050457","volume":"57","author":"ND Reeves","year":"2021","unstructured":"Reeves ND, Orlando G, Brown SJ. Sensory-motor mechanisms increasing falls risk in diabetic peripheral neuropathy. Medicina (Kaunas). 2021;57(5):457. https:\/\/doi.org\/10.3390\/medicina57050457.","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"2408_CR81","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s40620-020-00840-y","volume":"34","author":"A Sabatino","year":"2021","unstructured":"Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347\u201372. https:\/\/doi.org\/10.1007\/s40620-020-00840-y.","journal-title":"J Nephrol"},{"issue":"2","key":"2408_CR82","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jcsm.13425","volume":"15","author":"MP Duarte","year":"2024","unstructured":"Duarte MP, Almeida LS, Neri SGR, Oliveira JS, Wilkinson TJ, Ribeiro HS, et al. Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2024;15(2):501\u201312. https:\/\/doi.org\/10.1002\/jcsm.13425.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2408_CR83","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/cia.S459492","volume":"19","author":"N Alissa","year":"2024","unstructured":"Alissa N, Shipper AG, Zilliox L, Westlake KP. A systematic review of the effect of physical rehabilitation on balance in people with diabetic peripheral neuropathy who are at risk of falling. Clin Interv Aging. 2024;19:1325\u201339. https:\/\/doi.org\/10.2147\/cia.S459492.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"2408_CR84","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.clnu.2022.01.024","volume":"41","author":"D Volkert","year":"2022","unstructured":"Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Hooper L, Kiesswetter E, et al. ESPEN practical guideline: clinical nutrition and hydration in geriatrics. Clin Nutr. 2022;41(4):958\u201389. https:\/\/doi.org\/10.1016\/j.clnu.2022.01.024.","journal-title":"Clin Nutr"},{"issue":"11","key":"2408_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/nu13113729","volume":"13","author":"F Takahashi","year":"2021","unstructured":"Takahashi F, Hashimoto Y, Kaji A, Sakai R, Kawate Y, Okamura T, et al. Association between Geriatric Nutrition Risk Index and the presence of sarcopenia in people with type 2 diabetes mellitus: a cross-sectional study. Nutrients. 2021;13(11):3729. https:\/\/doi.org\/10.3390\/nu13113729.","journal-title":"Nutrients"},{"issue":"11","key":"2408_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111911","volume":"12","author":"AJ Sinclair","year":"2022","unstructured":"Sinclair AJ, Abdelhafiz AH. Multimorbidity, frailty and diabetes in older people-identifying interrelationships and outcomes. J Pers Med. 2022;12(11):1911. https:\/\/doi.org\/10.3390\/jpm12111911.","journal-title":"J Pers Med"},{"issue":"5","key":"2408_CR87","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00223-020-00742-y","volume":"107","author":"P Anagnostis","year":"2020","unstructured":"Anagnostis P, Gkekas NK, Achilla C, Pananastasiou G, Taouxidou P, Mitsiou M, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcif Tissue Int. 2020;107(5):453\u201363. https:\/\/doi.org\/10.1007\/s00223-020-00742-y.","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2408_CR88","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","volume":"51","author":"N Musi","year":"2002","unstructured":"Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51(7):2074\u201381. https:\/\/doi.org\/10.2337\/diabetes.51.7.2074.","journal-title":"Diabetes"},{"issue":"27","key":"2408_CR89","doi-asserted-by":"publisher","first-page":"23977","DOI":"10.1074\/jbc.C200171200","volume":"277","author":"DR Bolster","year":"2002","unstructured":"Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem. 2002;277(27):23977\u201380. https:\/\/doi.org\/10.1074\/jbc.C200171200.","journal-title":"J Biol Chem"},{"issue":"6","key":"2408_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13039","volume":"18","author":"RG Walton","year":"2019","unstructured":"Walton RG, Dungan CM, Long DE, Tuggle SC, Kosmac K, Peck BD, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: a randomized, double-blind, placebo-controlled, multicenter trial: the MASTERS trial. Aging Cell. 2019;18(6):e13039. https:\/\/doi.org\/10.1111\/acel.13039.","journal-title":"Aging Cell"},{"issue":"3","key":"2408_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2025.100695","volume":"6","author":"MD Witham","year":"2025","unstructured":"Witham MD, McDonald C, Wilson N, Rennie KJ, Bardgett M, Bradley P, et al. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial. Lancet Healthy Longev. 2025;6(3):100695. https:\/\/doi.org\/10.1016\/j.lanhl.2025.100695.","journal-title":"Lancet Healthy Longev"},{"issue":"4","key":"2408_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.102998","volume":"55","author":"R Qaisar","year":"2024","unstructured":"Qaisar R, Karim A, Muhammad T, Iqbal MS, Ahmad F. Metformin improves sarcopenia-related quality of life in geriatric adults: a randomized controlled trial. Arch Med Res. 2024;55(4):102998. https:\/\/doi.org\/10.1016\/j.arcmed.2024.102998.","journal-title":"Arch Med Res"},{"key":"2408_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105587","volume":"127","author":"R Qaisar","year":"2024","unstructured":"Qaisar R, Javed M, Khan IM, Ahmad F, Karim A. Metformin improves skeletal muscle and physical capacity by stabilizing neuromuscular junction in older adults. Arch Gerontol Geriatr. 2024;127:105587. https:\/\/doi.org\/10.1016\/j.archger.2024.105587.","journal-title":"Arch Gerontol Geriatr"},{"issue":"2","key":"2408_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.17925\/ee.2024.20.2.7","volume":"20","author":"M Atkinson","year":"2024","unstructured":"Atkinson M, Gharti P, Min T. Metformin use and vitamin B12 deficiency in people with type 2 diabetes: what are the risk factors? A mini-systematic review touchREV Endocrinol. 2024;20(2):42\u201353. https:\/\/doi.org\/10.17925\/ee.2024.20.2.7.","journal-title":"A mini-systematic review. touchREV Endocrinol."},{"key":"2408_CR95","doi-asserted-by":"publisher","unstructured":"Safety update: metformin and vitamin B(12). Drug Ther Bull. 2022;60(9):131. https:\/\/doi.org\/10.1136\/dtb.2022.000039.","DOI":"10.1136\/dtb.2022.000039"},{"key":"2408_CR96","doi-asserted-by":"publisher","unstructured":"13. Older adults: standards of care in diabetes: 2026. Diabetes Care. 2026;49(Suppl. 1):S277\u201396. https:\/\/doi.org\/10.2337\/dc26-S013.","DOI":"10.2337\/dc26-S013"},{"issue":"2","key":"2408_CR97","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1172\/jci117731","volume":"95","author":"G Biolo","year":"1995","unstructured":"Biolo G, Declan Fleming RY, Wolfe RR. Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. J Clin Invest. 1995;95(2):811\u20139. https:\/\/doi.org\/10.1172\/jci117731.","journal-title":"J Clin Invest"},{"issue":"8","key":"2408_CR98","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1210\/jc.2009-2696","volume":"95","author":"KL Timmerman","year":"2010","unstructured":"Timmerman KL, Lee JL, Dreyer HC, Dhanani S, Glynn EL, Fry CS, et al. Insulin stimulates human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. J Clin Endocrinol Metab. 2010;95(8):3848\u201357. https:\/\/doi.org\/10.1210\/jc.2009-2696.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2408_CR99","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00125-009-1430-8","volume":"52","author":"S Fujita","year":"2009","unstructured":"Fujita S, Glynn EL, Timmerman KL, Rasmussen BB, Volpi E. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism. Diabetologia. 2009;52(9):1889\u201398. https:\/\/doi.org\/10.1007\/s00125-009-1430-8.","journal-title":"Diabetologia"},{"issue":"1","key":"2408_CR100","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2337\/db07-0887","volume":"57","author":"S Pereira","year":"2008","unstructured":"Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes. 2008;57(1):56\u201363. https:\/\/doi.org\/10.2337\/db07-0887.","journal-title":"Diabetes"},{"issue":"5","key":"2408_CR101","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/jn\/136.5.1249","volume":"136","author":"JA Bell","year":"2006","unstructured":"Bell JA, Volpi E, Fujita S, Cadenas JG, Sheffield-Moore M, Rasmussen BB. Skeletal muscle protein anabolic response to increased energy and insulin is preserved in poorly controlled type 2 diabetes. J Nutr. 2006;136(5):1249\u201355. https:\/\/doi.org\/10.1093\/jn\/136.5.1249.","journal-title":"J Nutr"},{"issue":"4","key":"2408_CR102","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jamda.2020.11.003","volume":"22","author":"K Sugimoto","year":"2021","unstructured":"Sugimoto K, Ikegami H, Takata Y, Katsuya T, Fukuda M, Akasaka H, et al. Glycemic control and insulin improve muscle mass and gait speed in type 2 diabetes: the MUSCLES-DM study. J Am Med Dir Assoc. 2021;22(4):834-8.e1. https:\/\/doi.org\/10.1016\/j.jamda.2020.11.003.","journal-title":"J Am Med Dir Assoc"},{"issue":"9","key":"2408_CR103","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2337\/dc20-0316","volume":"43","author":"AK Lee","year":"2020","unstructured":"Lee AK, Juraschek SP, Windham BG, Lee CJ, Sharrett AR, Coresh J, et al. Severe hypoglycemia and risk of falls in type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2020;43(9):2060\u20135. https:\/\/doi.org\/10.2337\/dc20-0316.","journal-title":"Diabetes Care"},{"key":"2408_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100162","volume":"12","author":"HH Moffet","year":"2023","unstructured":"Moffet HH, Huang ES, Liu JY, Parker MM, Lipska KJ, Laiteerapong N, et al. Severe hypoglycemia and falls in older adults with diabetes: the Diabetes & Aging Study. Diabet Epidemiol Manag. 2023;12:100162. https:\/\/doi.org\/10.1016\/j.deman.2023.100162.","journal-title":"Diabet Epidemiol Manag."},{"issue":"5","key":"2408_CR105","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamainternmed.2020.9176","volume":"181","author":"MC Bradley","year":"2021","unstructured":"Bradley MC, Chillarige Y, Lee H, Wu X, Parulekar S, Muthuri S, et al. Severe hypoglycemia risk with long-acting insulin analogs vs neutral protamine Hagedorn insulin. JAMA Intern Med. 2021;181(5):598\u2013607. https:\/\/doi.org\/10.1001\/jamainternmed.2020.9176.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2408_CR106","doi-asserted-by":"publisher","first-page":"e2132215","DOI":"10.1001\/jamanetworkopen.2021.32215","volume":"4","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos AS, Kahkoska AR, Pate V, Bradley MC, Niznik J, Thorpe C, et al. Deintensification of reatment with sulfonylurea and insulin after severe hypoglycemia among older adults with diabetes. JAMA Netw Open. 2021;4(11):e2132215. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.32215.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2408_CR107","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/s2213-8587(24)00372-3","volume":"13","author":"M Munshi","year":"2025","unstructured":"Munshi M, Kahkoska AR, Neumiller JJ, Alexopoulos AS, Allen NA, Cukierman-Yaffe T, et al. Realigning diabetes regimens in older adults: a 4S pathway to guide simplification and deprescribing strategies. Lancet Diabetes Endocrinol. 2025;13(5):427\u201337. https:\/\/doi.org\/10.1016\/s2213-8587(24)00372-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2408_CR108","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"2408_CR109","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10193","key":"2408_CR110","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"16","key":"2408_CR111","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/circulationaha.124.067676","volume":"150","author":"J Linge","year":"2024","unstructured":"Linge J, Birkenfeld AL, Neeland IJ. Muscle ass and Gglucagon-like peptide-1 eceptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150(16):1288\u201398. https:\/\/doi.org\/10.1161\/circulationaha.124.067676.","journal-title":"Circulation"},{"issue":"Suppl. 4","key":"2408_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl. 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728.","journal-title":"Diabetes Obes Metab"},{"key":"2408_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113.","journal-title":"Metabolism"},{"key":"2408_CR114","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.2147\/dddt.S531778","volume":"19","author":"Q Ren","year":"2025","unstructured":"Ren Q, Zhi L, Liu H. Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study. Drug Des Devel Ther. 2025;19:5645\u201352. https:\/\/doi.org\/10.2147\/dddt.S531778.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2408_CR115","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/bcp.70253","volume":"92","author":"R Qaisar","year":"2026","unstructured":"Qaisar R, Khan IU, Rehman AU, Iqbal MS, Ahmad F, Karim A. Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus. Br J Clin Pharmacol. 2026;92(1):149\u201361. https:\/\/doi.org\/10.1002\/bcp.70253.","journal-title":"Br J Clin Pharmacol"},{"key":"2408_CR116","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/ppa.S97383","volume":"10","author":"M Rondanelli","year":"2016","unstructured":"Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10:407\u201313. https:\/\/doi.org\/10.2147\/ppa.S97383.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2408_CR117","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14740\/jocmr3647","volume":"11","author":"S Ishii","year":"2019","unstructured":"Ishii S, Nagai Y, Sada Y, Fukuda H, Nakamura Y, Matsuba R, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series. J Clin Med Res. 2019;11(3):219\u201324. https:\/\/doi.org\/10.14740\/jocmr3647.","journal-title":"J Clin Med Res"},{"key":"2408_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-018-0295-6","volume":"15","author":"TT Yin","year":"2018","unstructured":"Yin TT, Bi Y, Li P, Shen SM, Wang WM, Jiang C, et al. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutr Metab (Lond). 2018;15:67. https:\/\/doi.org\/10.1186\/s12986-018-0295-6.","journal-title":"Nutr Metab (Lond)"},{"issue":"3","key":"2408_CR119","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63(3):473\u201385. https:\/\/doi.org\/10.1007\/s00125-019-05065-8.","journal-title":"Diabetologia"},{"issue":"6","key":"2408_CR120","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/s2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, Neeland IJ, Dahlqvist Leinhard O, Fern\u00e1ndez Land\u00f3 L, Bray R, Linge J, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(6):482\u201393. https:\/\/doi.org\/10.1016\/s2213-8587(25)00027-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2408_CR121","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, Cao D, Harris C, Gibble TH, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2408_CR122","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/dom.14712","volume":"24","author":"VER Parker","year":"2022","unstructured":"Parker VER, Hoang T, Schlichthaar H, Gibb FW, Wenzel B, Posch MG, et al. Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2022;24(7):1360\u20139. https:\/\/doi.org\/10.1111\/dom.14712.","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"2408_CR123","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392(22):2215\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2411528.","journal-title":"N Engl J Med"},{"issue":"5","key":"2408_CR124","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, et al. SGLT2 inhibitors: the ew standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther. 2024;15(5):1099\u2013124. https:\/\/doi.org\/10.1007\/s13300-024-01550-5.","journal-title":"Diabetes Ther"},{"issue":"5","key":"2408_CR125","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974\u201389. https:\/\/doi.org\/10.1016\/j.kint.2022.08.012.","journal-title":"Kidney Int"},{"issue":"12","key":"2408_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279889","volume":"17","author":"R Pan","year":"2022","unstructured":"Pan R, Zhang Y, Wang R, Xu Y, Ji H, Zhao Y. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(12):e0279889. https:\/\/doi.org\/10.1371\/journal.pone.0279889.","journal-title":"PLoS ONE"},{"issue":"4","key":"2408_CR127","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.eprac.2025.12.010","volume":"32","author":"S Yamamoto","year":"2026","unstructured":"Yamamoto S, Yuge H, Okada H, Saijo Y, Hasegawa Y, Nakajima H, et al. A meta-analysis of body composition changes associated with long-term use of sodium-glucose cotransporter 2 inhibitors. Endocr Pract. 2026;32(4):644\u201350. https:\/\/doi.org\/10.1016\/j.eprac.2025.12.010.","journal-title":"Endocr Pract"},{"issue":"12","key":"2408_CR128","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/dom.15249","volume":"25","author":"D Yabe","year":"2023","unstructured":"Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab. 2023;25(12):3538\u201348. https:\/\/doi.org\/10.1111\/dom.15249.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2408_CR129","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020\u201331. https:\/\/doi.org\/10.1210\/jc.2011-2260.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2408_CR130","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","volume":"25","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018;25(6):467\u201376. https:\/\/doi.org\/10.5551\/jat.40873.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"2408_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21486-9","volume":"12","author":"YH Zeng","year":"2022","unstructured":"Zeng YH, Liu SC, Lee CC, Sun FJ, Liu JJ. Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin. Sci Rep. 2022;12(1):17065. https:\/\/doi.org\/10.1038\/s41598-022-21486-9.","journal-title":"Sci Rep"},{"issue":"4","key":"2408_CR132","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf075","volume":"18","author":"T Yajima","year":"2025","unstructured":"Yajima T, Noda K, Yajima K. Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease. Clin Kidney J. 2025;18(4):sfaf075. https:\/\/doi.org\/10.1093\/ckj\/sfaf075.","journal-title":"Clin Kidney J"},{"issue":"7","key":"2408_CR133","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/medicina61071152","volume":"61","author":"D \u00c7etin","year":"2025","unstructured":"\u00c7etin D, Bilgili E, Koma\u00e7 \u00d6, Yeti\u015fken M, G\u00fcney E. Effects of empagliflozin on sarcopenia risk, body composition, and muscle strength in type 2 diabetes: a 24-week real-world observational study. Medicina (Kaunas). 2025;61(7):1152. https:\/\/doi.org\/10.3390\/medicina61071152.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"2408_CR134","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/jdi.14283","volume":"15","author":"H Umegaki","year":"2024","unstructured":"Umegaki H. Management of older adults with diabetes mellitus: perspective from geriatric medicine. J Diabetes Investig. 2024;15(10):1347\u201354. https:\/\/doi.org\/10.1111\/jdi.14283.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"2408_CR135","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jcsm.12838","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Zhao Y, Chen S, Shao H. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle. 2021;12(6):1368\u201379. https:\/\/doi.org\/10.1002\/jcsm.12838.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"10","key":"2408_CR136","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jamda.2016.04.016","volume":"17","author":"MR Rizzo","year":"2016","unstructured":"Rizzo MR, Barbieri M, Fava I, Desiderio M, Coppola C, Marfella R, et al. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc. 2016;17(10):896\u2013901. https:\/\/doi.org\/10.1016\/j.jamda.2016.04.016.","journal-title":"J Am Med Dir Assoc"},{"key":"2408_CR137","doi-asserted-by":"publisher","unstructured":"Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, et al. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabetes Metab Res Rev. 2018;34(2). https:\/\/doi.org\/10.1002\/dmrr.2957.","DOI":"10.1002\/dmrr.2957"},{"issue":"5","key":"2408_CR138","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015766","volume":"7","author":"M Koshizaka","year":"2017","unstructured":"Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, et al. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study). BMJ Open. 2017;7(5):e015766. https:\/\/doi.org\/10.1136\/bmjopen-2016-015766.","journal-title":"BMJ Open"},{"key":"2408_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2022.111832","volume":"164","author":"C Sencan","year":"2022","unstructured":"Sencan C, Dost FS, Ates Bulut E, Isik AT. DPP4 inhibitors as a potential therapeutic option for sarcopenia: a 6-month follow-up study in diabetic older patients. Exp Gerontol. 2022;164:111832. https:\/\/doi.org\/10.1016\/j.exger.2022.111832.","journal-title":"Exp Gerontol"},{"issue":"7","key":"2408_CR140","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40266-013-0081-0","volume":"30","author":"KL Lapane","year":"2013","unstructured":"Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging. 2013;30(7):527\u201347. https:\/\/doi.org\/10.1007\/s40266-013-0081-0.","journal-title":"Drugs Aging"},{"issue":"2","key":"2408_CR141","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/dom.14254","volume":"23","author":"MA Espeland","year":"2021","unstructured":"Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, et al. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial. Diabetes Obes Metab. 2021;23(2):569\u201380. https:\/\/doi.org\/10.1111\/dom.14254.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2408_CR142","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.diabres.2015.05.009","volume":"109","author":"KL Lapane","year":"2015","unstructured":"Lapane KL, Jesdale BM, Dub\u00e9 CE, Pimentel CB, Rajpathak SN. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;109(2):411\u20139. https:\/\/doi.org\/10.1016\/j.diabres.2015.05.009.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"2408_CR143","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1532-5415.1996.tb03729.x","volume":"44","author":"RI Shorr","year":"1996","unstructured":"Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751\u20135. https:\/\/doi.org\/10.1111\/j.1532-5415.1996.tb03729.x.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"2408_CR144","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s40520-020-01736-4","volume":"33","author":"Y Tao","year":"2021","unstructured":"Tao Y, E M, Shi J, Zhang Z. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study. Aging Clin Exp Res. 2021;33(8):2133\u20139. https:\/\/doi.org\/10.1007\/s40520-020-01736-4.","journal-title":"Aging Clin Exp Res"},{"issue":"10","key":"2408_CR145","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2337\/dc25-0517","volume":"48","author":"S Shabnam","year":"2025","unstructured":"Shabnam S, Ling S, Gillies C, Zaccardi F, Choudhary P, Khunti K, et al. Glucose control, sulfonylureas, and insulin treatment in older adults with type 2 diabetes and risk of falls and fractures: an observational study. Diabetes Care. 2025;48(10):1744\u201351. https:\/\/doi.org\/10.2337\/dc25-0517.","journal-title":"Diabetes Care"},{"key":"2408_CR146","doi-asserted-by":"publisher","unstructured":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052\u201381. https:\/\/doi.org\/10.1111\/jgs.18372.","DOI":"10.1111\/jgs.18372"},{"issue":"8","key":"2408_CR147","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/oby.2010.327","volume":"19","author":"MK Shea","year":"2011","unstructured":"Shea MK, Nicklas BJ, Marsh AP, Houston DK, Miller GD, Isom S, et al. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss. Obesity (Silver Spring). 2011;19(8):1636\u201346. https:\/\/doi.org\/10.1038\/oby.2010.327.","journal-title":"Obesity (Silver Spring)"},{"key":"2408_CR148","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","volume":"68","author":"ZN Zhu","year":"2014","unstructured":"Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone. 2014;68:115\u201323. https:\/\/doi.org\/10.1016\/j.bone.2014.08.010.","journal-title":"Bone"},{"issue":"3","key":"2408_CR149","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jc.2016-3237","volume":"102","author":"CM Viscoli","year":"2017","unstructured":"Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102(3):914\u201322. https:\/\/doi.org\/10.1210\/jc.2016-3237.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2408_CR150","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.18632\/aging.204643","volume":"15","author":"CL Yen","year":"2023","unstructured":"Yen CL, Wu CY, Tsai CY, Lee CC, Li YJ, Peng WS, et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. Aging (Albany NY). 2023;15(7):2721\u201333. https:\/\/doi.org\/10.18632\/aging.204643.","journal-title":"Aging (Albany NY)."},{"issue":"10","key":"2408_CR151","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180\u20138. https:\/\/doi.org\/10.1001\/jama.298.10.1180.","journal-title":"JAMA"},{"issue":"2","key":"2408_CR152","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","volume":"11","author":"AV Hernandez","year":"2011","unstructured":"Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115\u201328. https:\/\/doi.org\/10.2165\/11587580-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"2408_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13563","volume":"16","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wang L, Dong Z, Xia B, Pang S. Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat type 2 diabetes: a review study. J Diabetes. 2024;16(6):e13563. https:\/\/doi.org\/10.1111\/1753-0407.13563.","journal-title":"J Diabetes"},{"issue":"475","key":"2408_CR154","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau3441","volume":"11","author":"A Vella","year":"2019","unstructured":"Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019;11(475):eaau3441. https:\/\/doi.org\/10.1126\/scitranslmed.aau3441.","journal-title":"Sci Transl Med"},{"key":"2408_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1041044","volume":"9","author":"Y Yu","year":"2022","unstructured":"Yu Y, Yang X, Tong K, Yin S, Hu G, Zhang F, et al. Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: a meta-analysis and trial sequential analysis. Front Cardiovasc Med. 2022;9:1041044. https:\/\/doi.org\/10.3389\/fcvm.2022.1041044.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"2408_CR156","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2337\/dbi25-0028","volume":"74","author":"L Agius","year":"2025","unstructured":"Agius L, Magnuson MA. Glucokinase activators: a humbling lesson in drug development. Diabetes. 2025;74(8):1339\u201341. https:\/\/doi.org\/10.2337\/dbi25-0028.","journal-title":"Diabetes"},{"issue":"2","key":"2408_CR157","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/cts.13174","volume":"15","author":"J Miao","year":"2022","unstructured":"Miao J, Fu P, Ren S, Hu C, Wang Y, Jiao C, et al. Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator. Clin Transl Sci. 2022;15(2):548\u201357. https:\/\/doi.org\/10.1111\/cts.13174.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2408_CR158","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1111\/dom.16312","volume":"27","author":"R Hua","year":"2025","unstructured":"Hua R, Shi M, Chow E, Yang A, Cheung YT. Genetic evidence for the effects of glucokinase activation on frailty-related outcomes: a Mendelian randomisation study. Diabetes Obes Metab. 2025;27(6):3072\u201383. https:\/\/doi.org\/10.1111\/dom.16312.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"2408_CR159","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-021-01589-9","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Imeglimin hydrochloride: first approval. Drugs. 2021;81(14):1683\u201390. https:\/\/doi.org\/10.1007\/s40265-021-01589-9.","journal-title":"Drugs"},{"issue":"11","key":"2408_CR160","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s13300-024-01639-x","volume":"15","author":"T Oyanagi","year":"2024","unstructured":"Oyanagi T, Kawanabe S, Tsukiyama H, Nishine A, Nakamura Y, Nakagawa T, et al. The effects of imeglimin on muscle strength in patients with type 2 diabetes: a prospective cohort study. Diabetes Ther. 2024;15(11):2323\u201336. https:\/\/doi.org\/10.1007\/s13300-024-01639-x.","journal-title":"Diabetes Ther."},{"issue":"7","key":"2408_CR161","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","volume":"14","author":"SS Johnston","year":"2012","unstructured":"Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(7):634\u201343. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01583.x.","journal-title":"Diabetes Obes Metab"},{"key":"2408_CR162","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ"},{"issue":"4","key":"2408_CR163","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"2408_CR164","doi-asserted-by":"publisher","unstructured":"KDIGO 2022 Clinical Practice Guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5s):S1\u2013127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"10","key":"2408_CR165","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"2","key":"2408_CR166","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Petrie JR, Sesti G, Mannucci E, Courr\u00e8ges JP, Lindegaard ML, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231\u201341. https:\/\/doi.org\/10.2337\/dc15-0165.","journal-title":"Diabetes Care"},{"issue":"5","key":"2408_CR167","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1007\/s12603-019-1181-2","volume":"23","author":"L Hou","year":"2019","unstructured":"Hou L, Lei Y, Li X, Huo C, Jia X, Yang J, et al. Effect of protein supplementation combined with resistance training on muscle mass, strength andfFunction in the elderly: a systematic review and eta-Anaalysis. J Nutr Health Aging. 2019;23(5):4518. https:\/\/doi.org\/10.1007\/s12603-019-1181-2.","journal-title":"J Nutr Health Aging"},{"key":"2408_CR168","doi-asserted-by":"publisher","unstructured":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes: 2026. Diabetes Care. 2026;49(Suppl. 1):S183\u2013215. https:\/\/doi.org\/10.2337\/dc26-S009","DOI":"10.2337\/dc26-S009"},{"issue":"1","key":"2408_CR169","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0899-9007(95)00017-8","volume":"12","author":"MA Laskey","year":"1996","unstructured":"Laskey MA. Dual-energy X-ray absorptiometry and body composition. Nutrition. 1996;12(1):45\u201351. https:\/\/doi.org\/10.1016\/0899-9007(95)00017-8.","journal-title":"Nutrition"},{"issue":"2","key":"2408_CR170","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/jappl.2000.89.2.465","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985). 2000;89(2):465\u201371. https:\/\/doi.org\/10.1152\/jappl.2000.89.2.465.","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"2408_CR171","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-2002-33145","volume":"23","author":"C O'Brien","year":"2002","unstructured":"O\u2019Brien C, Young AJ, Sawka MN. Bioelectrical impedance to estimate changes in hydration status. Int J Sports Med. 2002;23(5):361\u20136. https:\/\/doi.org\/10.1055\/s-2002-33145.","journal-title":"Int J Sports Med"},{"issue":"2","key":"2408_CR172","doi-asserted-by":"publisher","first-page":"M85","DOI":"10.1093\/geronj\/49.2.m85","volume":"49","author":"JM Guralnik","year":"1994","unstructured":"Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94. https:\/\/doi.org\/10.1093\/geronj\/49.2.m85.","journal-title":"J Gerontol"},{"issue":"1","key":"2408_CR173","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2010.1923","volume":"305","author":"S Studenski","year":"2011","unstructured":"Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50\u20138. https:\/\/doi.org\/10.1001\/jama.2010.1923.","journal-title":"JAMA"},{"issue":"2","key":"2408_CR174","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1249\/MSS.0b013e3181eb6265","volume":"43","author":"MD Peterson","year":"2011","unstructured":"Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med Sci Sports Exerc. 2011;43(2):249\u201358. https:\/\/doi.org\/10.1249\/MSS.0b013e3181eb6265.","journal-title":"Med Sci Sports Exerc"},{"issue":"8","key":"2408_CR175","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","volume":"14","author":"J Bauer","year":"2013","unstructured":"Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542\u201359. https:\/\/doi.org\/10.1016\/j.jamda.2013.05.021.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"2408_CR176","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","volume":"12","author":"WD Strain","year":"2021","unstructured":"Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an Expert Consensus Statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12(5):1227\u201347. https:\/\/doi.org\/10.1007\/s13300-021-01035-9.","journal-title":"Diabetes Ther."},{"key":"2408_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389. https:\/\/doi.org\/10.3389\/fendo.2019.00389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2408_CR178","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14283\/jfa.2017.39","volume":"7","author":"AJ Sinclair","year":"2017","unstructured":"Sinclair AJ, Abdelhafiz A, Dunning T, Izquierdo M, Rodriguez Manas L, Bourdel-Marchasson I, et al. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. 2017;7(1):10\u201320. https:\/\/doi.org\/10.14283\/jfa.2017.39.","journal-title":"J Frailty Aging"},{"issue":"10","key":"2408_CR179","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2337\/diacare.25.10.1729","volume":"25","author":"DW Dunstan","year":"2002","unstructured":"Dunstan DW, Daly RM, Owen N, Jolley D, De Courten M, Shaw J, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002;25(10):1729\u201336. https:\/\/doi.org\/10.2337\/diacare.25.10.1729.","journal-title":"Diabetes Care"},{"issue":"12","key":"2408_CR180","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2337\/diacare.25.12.2335","volume":"25","author":"C Castaneda","year":"2002","unstructured":"Castaneda C, Layne JE, Munoz-Orians L, Gordon PL, Walsmith J, Foldvari M, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002;25(12):2335\u201341. https:\/\/doi.org\/10.2337\/diacare.25.12.2335.","journal-title":"Diabetes Care"},{"issue":"17","key":"2408_CR181","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2011.576","volume":"305","author":"D Umpierre","year":"2011","unstructured":"Umpierre D, Ribeiro PA, Kramer CK, Leit\u00e3o CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790\u20139. https:\/\/doi.org\/10.1001\/jama.2011.576.","journal-title":"JAMA"},{"issue":"4","key":"2408_CR182","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.clnu.2021.02.049","volume":"40","author":"R Kawano","year":"2021","unstructured":"Kawano R, Takahashi F, Hashimoto Y, Okamura T, Miki A, Kaji A, et al. Short energy intake is associated with muscle mass loss in older patients with type 2 diabetes: a prospective study of the KAMOGAWA-DM cohort. Clin Nutr. 2021;40(4):1613\u201320. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.049.","journal-title":"Clin Nutr"},{"issue":"7","key":"2408_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072335","volume":"13","author":"F Takahashi","year":"2021","unstructured":"Takahashi F, Hashimoto Y, Kaji A, Sakai R, Kawate Y, Okamura T, et al. Vitamin intake and loss of muscle mass in older people with ttype 2 diabetes: a prospective study of the KAMOGAWA-DM cohort. Nutrients. 2021;13(7):2335. https:\/\/doi.org\/10.3390\/nu13072335.","journal-title":"Nutrients"},{"issue":"6","key":"2408_CR184","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ajcnut.2023.04.021","volume":"117","author":"DK Houston","year":"2023","unstructured":"Houston DK, Marsh AP, Neiberg RH, Demons JL, Campos CL, Kritchevsky SB, et al. Vitamin D supplementation and muscle power, strength and physical performance in older adults: a randomized controlled trial. Am J Clin Nutr. 2023;117(6):1086\u201395. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.04.021.","journal-title":"Am J Clin Nutr"},{"key":"2408_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.919839","volume":"13","author":"FL Wei","year":"2022","unstructured":"Wei FL, Li T, Gao QY, Huang Y, Zhou CP, Wang W, et al. Association between vitamin D supplementation and fall prevention. Front Endocrinol (Lausanne). 2022;13:919839. https:\/\/doi.org\/10.3389\/fendo.2022.919839.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2408_CR186","doi-asserted-by":"publisher","DOI":"10.3390\/nu14112221","volume":"14","author":"SM Cornish","year":"2022","unstructured":"Cornish SM, Cordingley DM, Shaw KA, Forbes SC, Leonhardt T, Bristol A, et al. Effects of omega-3 supplementation alone and combined with resistance exercise on skeletal muscle in older adults: a systematic review and meta-analysis. Nutrients. 2022;14(11):2221. https:\/\/doi.org\/10.3390\/nu14112221.","journal-title":"Nutrients"},{"key":"2408_CR187","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.clnesp.2024.03.019","volume":"61","author":"Y Uchida","year":"2024","unstructured":"Uchida Y, Tsuji K, Ochi E. Effects of omega-3 fatty acids supplementation and resistance training on skeletal muscle. Clin Nutr ESPEN. 2024;61:189\u201396. https:\/\/doi.org\/10.1016\/j.clnesp.2024.03.019.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"2408_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s11556-025-00392-9","volume":"22","author":"S Liu","year":"2025","unstructured":"Liu S, Huang N, Wu W, OuYang X, Luo Y, Zhong Y, et al. The impact of creatine supplementation associated with resistance training on muscular strength and lean tissue mass in the aged: a systematic review and meta-analysis. Eur Rev Aging Phys Act. 2025;22(1):26. https:\/\/doi.org\/10.1186\/s11556-025-00392-9.","journal-title":"Eur Rev Aging Phys Act"},{"issue":"2","key":"2408_CR189","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00394-021-02710-0","volume":"61","author":"GH Bai","year":"2022","unstructured":"Bai GH, Tsai MC, Tsai HW, Chang CC, Hou WH. Effects of branched-chain amino acid-rich supplementation on EWGSOP2 criteria for sarcopenia in older adults: a systematic review and meta-analysis. Eur J Nutr. 2022;61(2):637\u201351. https:\/\/doi.org\/10.1007\/s00394-021-02710-0.","journal-title":"Eur J Nutr"},{"issue":"15","key":"2408_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/nu15153424","volume":"15","author":"I Cuyul-V\u00e1squez","year":"2023","unstructured":"Cuyul-V\u00e1squez I, Pezo-Navarrete J, Vargas-Arriagada C, Ortega-D\u00edaz C, Sep\u00falveda-Loyola W, Hirabara SM, et al. Effectiveness of whey protein supplementation during resistance exercise training on skeletal muscle mass and strength in older people with sarcopenia: a systematic review and meta-analysis. Nutrients. 2023;15(15):3424. https:\/\/doi.org\/10.3390\/nu15153424.","journal-title":"Nutrients"},{"issue":"5","key":"2408_CR191","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.70060","volume":"16","author":"A Ijaz","year":"2025","unstructured":"Ijaz A, Ain HBU, Tufail T, Mariam R, Noreen S, Amjad A, et al. Enhancing muscle quality: exploring leucine and whey protein in sarcopenic individuals. J Cachexia Sarcopenia Muscle. 2025;16(5):e70060. https:\/\/doi.org\/10.1002\/jcsm.70060.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2408_CR192","doi-asserted-by":"publisher","first-page":"1348212","DOI":"10.3389\/fmed.2024.1348212","volume":"11","author":"H Su","year":"2024","unstructured":"Su H, Zhou H, Gong Y, Xiang S, Shao W, Zhao X, et al. The effects of \u03b2-hydroxy-\u03b2-methylbutyrate or HMB-rich nutritional supplements on sarcopenia patients: a systematic review and meta-analysis. Front Med (Lausanne). 2024;11:1348212. https:\/\/doi.org\/10.3389\/fmed.2024.1348212.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"2408_CR193","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jpen.2756","volume":"49","author":"GL Jensen","year":"2025","unstructured":"Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Pisprasert V, et al. GLIM consensus approach to diagnosis of malnutrition: a 5-year update. JPEN J Parenter Enteral Nutr. 2025;49(4):414\u201327. https:\/\/doi.org\/10.1002\/jpen.2756.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"1","key":"2408_CR194","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2408_CR195","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-026-04204-0","volume":"32","author":"SB Heymsfield","year":"2026","unstructured":"Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869\u201382. https:\/\/doi.org\/10.1038\/s41591-026-04204-0.","journal-title":"Nat Med"},{"issue":"7","key":"2408_CR196","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/s41591-026-04440-4","volume":"32","author":"RE Pratley","year":"2026","unstructured":"Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026;32(7):2673\u20138. https:\/\/doi.org\/10.1038\/s41591-026-04440-4.","journal-title":"Nat Med"},{"key":"2408_CR197","unstructured":"ClinicalTrials.gov. A study to test if trevogrumab or trevogrumab with garetosmab when taken with semaglutide is safe and how well they work in adult patients with obesity for weight loss, fat loss, and lean mass preservation (COURAGE). NCT06299098. https:\/\/clinicaltrials.gov\/study\/NCT06299098. [Accessed 31 Jul 2026]."},{"key":"2408_CR198","unstructured":"Regeneron Pharmaceuticals. Results from phase 2 COURAGE trial demonstrating potential to improve quality of GLP-1 receptor agonist-induced weight loss by preserving lean mass, presented at EASD. 2025. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/results-phase-2-courage-trial-demonstrating-potential-improve\/. [Accessed 31 Jul 2026]."},{"key":"2408_CR199","unstructured":"ClinicalTrials.gov. A study of bimagrumab (LY3985863) and tirzepatide (LY3298176), alone or in combination, in participants with obesity or overweight with type 2 diabetes. NCT06901349. https:\/\/clinicaltrials.gov\/study\/NCT06901349. [Accessed 31 Jul 2026]."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02408-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02408-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02408-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:17:04Z","timestamp":1792275424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02408-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":199,"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02408-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JZ, XZ and SS: literature search and writing (original draft and editing). SS: figure preparation. LZ: conceptualizsation, supervision, framework development and writing (review and editing). All authors reviewed and approved the final manuscript. All authors reviewed and refined the framework, read and approved the final manuscript, and agree to be accountable for the work.","order":1,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jing Zhang, Xiaodan Zhai, Sha Sha and Le Zhang have no conflicts of interest that are directly relevant to the content of this article.","order":4,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tools were used solely for language editing and refinement. The authors take full responsibility for the final content of the manuscript.","order":8,"name":"Ethics","label":"AI Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}